In 2013, University of Virginia researcher Michael McConnell published research that would forever change how scientists study brain cells.
McConnell and a team of nationwide collaborators discovered a genetic mosaic in the brains neurons, proving that brain cells are not exact replicas of each other, and that each individual neuron contains a slightly different genetic makeup.
McConnell, an assistant professor in the School of Medicines Department of Biochemistry and Molecular Genetics, has been using this new information to investigate how variations in individual neurons impact neuropsychiatric disorders like schizophrenia and epilepsy. With a recent $50,000 grant from the Bow Foundation, McConnell will expand his research to explore the cause of a rare genetic disorder known as GNAO1 so named for the faulty protein-coding gene that is its likely source.
GNAO1 causes seizures, movement disorders and developmental delays. Currently, only 50 people worldwide are known to have the disease. The Bow Foundation seeks to increase awareness so that other probable victims of the disorder can be properly diagnosed and to raise funds for further research and treatment.
UVA Today recently sat down with McConnell to find out more about how GNAO1 fits into his broader research and what his continued work means for all neuropsychiatric disorders.
Q. Can you explain the general goals of your lab?
A. My lab has two general directions. One is brain somatic mosaicism, which is a finding that different neurons in the brain have different genomes from one another. We usually think every cell in a single persons body has the same blueprint for how they develop and what they become. It turns out that blueprint changes a little bit in the neurons from neuron to neuron. So you have slightly different versions of the same blueprint and we want to know what that means.
The second area of our work focuses on a new technology called induced pluripotent stem cells, or iPSCs. The technology permits us to make stem cell from skin cells. We can do this with patients, and use the stem cells to make specific cell types with same genetic mutations that are in the patients. That lets us create and study the persons brain cells in a dish. So now, if that person has a neurological disease, we can in a dish study that persons disease and identify drugs that alter the disease. Its a very personalized medicine approach to that disease.
Q. Does cell-level genomic variety exist in other areas of the body outside the central nervous system?
A. Every cell in your body has mutations of one kind or another, but brain cells are there for your whole life, so the differences have a bigger impact there. A skin cell is gone in a month. An intestinal cell is gone in a week. Any changes in those cells will rarely have an opportunity to cause a problem unless they cause a tumor.
Q. How does your research intersect with the goals of the Bow Foundation?
A. Let me back up to a little bit of history on that. When I got to UVA four years ago, I started talking quite a lot with Howard Goodkin and Mark Beenhakker. Mark is an assistant professor in pharmacology. Howard is a pediatric neurologist and works with children with epilepsy. I had this interest in epilepsy and UVA has a historic and current strength in epilepsy research.
We started talking about how to use iPSCs the technology that we use to study mosaicism to help Howards patients. As we talked about it and I learned more about epilepsy, we quickly realized that there are a substantial number of patients with epilepsy or seizure disorders where we cant do a genetic test to figure out what drug to use on those patients.
Clinical guidance, like Howards expertise, allows him to make a pretty good diagnosis and know what drugs to try first and second and third. But around 30 percent of children that come in with epilepsy never find the drug that works, and theyre in for a lifetime of trial-and-error. We realized that we could use iPSC-derived neurons to test drugs in the dish instead of going through all of the trial-and-error with patients. Thats the bigger project that weve been moving toward.
The Bow Foundation was formed by patient advocates after this rare genetic mutation in GNAO1 was identified. GNAO1 is a subunit of a G protein-coupled receptor; some mutations in this receptor can lead to epilepsy while others lead to movement disorders.
Were still trying to learn about these patients, and the biggest thing the Bow Foundation is doing is trying to address that by creating a patient registry. At the same time, the foundation has provided funds for us to start making and testing iPSCs and launch this approach to personalized medicine for epilepsy.
In the GNAO1 patients, we expect to be able to study their neurons in a dish and understand why they behave differently, why the electrical activity in their brain is different or why they develop differently.
Q. What other more widespread disorders, in addition to schizophrenia and epilepsy, are likely to benefit from your research?
A. Im part of a broader project called the Brain Somatic Mosaicism Network that is conducting research on diseases that span the neuropsychiatric field. Our lab covers schizophrenia, but other nodes within that network are researching autism, bipolar disorder, Tourette syndrome and other psychiatric diseases where the genetic cause is difficult to identify. Thats the underlying theme.
- COVID-19 Stem Cell Therapies Pipeline, 2020 Report - ResearchAndMarkets.com - Business Wire - May 9th, 2020
- Role of science highlighted in pandemic fight - Chinadaily.com.cn - - May 9th, 2020
- UB investigators uncover cellular mechanism involved in Krabbe disease - UB Now: News and views for UB faculty and staff - University at Buffalo... - May 9th, 2020
- Gilbert Paterson band students to participate in worldwide documentary - Medicine Hat News - May 9th, 2020
- Heard On Sundial: Reopening Miami-Dade And The Keys, And Stem Cell Treatment For Coronavirus - WLRN - May 7th, 2020
- Researchers Convert Astrocytes to Neurons In Vivo to Treat... : Neurology Today - LWW Journals - May 7th, 2020
- Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New Eng - PharmiWeb.com - May 7th, 2020
- BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union - GlobeNewswire - May 7th, 2020
- Characterization and Immunomodulation of Canine Amniotic Membrane Stem | SCCAA - Dove Medical Press - May 7th, 2020
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy - BioSpace - May 7th, 2020
- Navigating cancer as a young adult: 'I'm trying to figure out who I am' - Stanford Medical Center Report - May 7th, 2020
- Orgenesis leads the charge at an exciting time for cell and gene therapy - Proactive Investors USA & Canada - May 7th, 2020
- DIABETES RESEARCH INSTITUTE FOUNDATION RECEIVES $3 MILLION GIFT FROM NORTH AMERICA'S BUILDING TRADES UNIONS TO FUND CELL THERAPY FOR COVID-19 -... - May 7th, 2020
- End-use Industries of Stem Cell Assay Product Witness Unparalleled Slowdown Induced by Global Outbreak of COVID-361 - 3rd Watch News - May 7th, 2020
- FDA Approves Tabrecta, the First Targeted Drug for Patients with Non-Small Cell Lung Cancer and MET exon 14 - Curetoday.com - May 7th, 2020
- UAE stem cell therapy: Revolutionary treatment helps cure COVID-19 patients - Gulf News - May 3rd, 2020
- Institute for Stem Cell Science and Regenerative Medicine ... - April 29th, 2020
- Scientists from Universities in Russia and Ukraine Collaborate to Research on New Approaches to Treat Obesity and Diabetes - QS WOW News - April 29th, 2020
- Organoids: Exploring Liver Cancer Initiation and the Possibilities of Personalized Glioblastoma Treatment - Technology Networks - April 29th, 2020
- Cell Culture Protein Surface Coating Market Competitive Analysis and Forecast 2017-2025 - Latest Herald - April 29th, 2020
- Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 - BioSpace - April 29th, 2020
- Stem Cell Treatment Options | National Stem Cell Clinic - April 28th, 2020
- Impact of COVID-19 on Stem Cell Assay Market In-Depth Analysis And Forecast 2020-2027 | By Top Key Players Merck & Co., Thermo Fisher Scientific,... - April 28th, 2020
- Dr Annalisa Jenkins on healthcare and biotech investments for family offices - Campden FB - April 28th, 2020
- Researcher says stem cell activation could lie at root of health effects of many natural products - NutraIngredients-usa.com - April 24th, 2020
- Researchers use cell therapy to recover damaged brain areas in mice that suffered - Mirage News - April 24th, 2020
- Scientists explore using CAR-T and other engineered immune cells to target COVID-19 - FierceBiotech - April 24th, 2020
- Lessons for medical profession during management of covid-19 pandemic: Is there a silver lining? - Elets - April 24th, 2020
- Scientists from IKBFU, Moscow and Kiev conducted research on treating obesity - Science Codex - April 24th, 2020
- Outlook on the Worldwide Amniotic Membrane Industry to 2027 - Strategic Recommendations for New Entrants - Yahoo Finance - April 24th, 2020
- Regenerative Medicine Market With Economic Growth And Five Forces Analysis By 2024 - Kentucky Journal 24 - April 21st, 2020
- Northwestern Scientists Awarded Top Honors for Achievement in Clinical Research - Northwestern University NewsCenter - April 17th, 2020
- Campus labs produce sample-preserving fluid for COVID-19 test kits - University of California - April 17th, 2020
- Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify - Technology Networks - April 17th, 2020
- What exactly are underlying conditions? And why people with them may experience more serious illness from coronavirus - Boston News, Weather, Sports |... - April 17th, 2020
- Pandemic reveals another shortcoming in preparation: Scattershot, chaotic research for treatments - Anchorage Daily News - April 17th, 2020
- Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Salamanca Press - April 15th, 2020
- UCSD scientists find possibilities for injured brain cells to be repaired - fox5sandiego.com - April 15th, 2020
- Stem cell therapies slowly gain traction as viable treatments for brain disorders - Science Magazine - April 15th, 2020
- CareDx Introduces AlloCell: Cell Therapy SurveillanceCareDx Announces Collaborations to Develop Cellular Therapy Diagnostics - BioSpace - April 15th, 2020
- NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter - BioSpace - April 15th, 2020
- Leading Urology KOLs Host Live Webinar Entitled The Protect PNS for OAB: A Wireless Uro-Stimulation Injectable Technology on April 29 at 5pm ET -... - April 15th, 2020
- Young-onset Parkinson's may start in the womb - Health24 - April 15th, 2020
- Horizon Research Fellow job with UNIVERSITY OF LEEDS | 203439 - Times Higher Education (THE) - April 15th, 2020
- What You Need to Know About the FDA's Approval of Opdivo-Yervoy for Hepatocellular Carcinoma - Curetoday.com - April 8th, 2020
- MSC-based therapies from Mesoblast, Cynata advance to tackle COVID-19 ARDS - BioWorld Online - April 8th, 2020
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) | DNA RNA and Cells | News... - April 8th, 2020
- AlloVir Appoints Ugo Capolino Perlingieri Head of Europe and Middle East Operations - Yahoo Finance - April 8th, 2020
- What does the public know about COVID-19? - University of Miami - April 8th, 2020
- India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 - IndianWeb2.com - April 8th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Size, Share and Growth Analysis Research Report by 2025. Top Companies are... - April 8th, 2020
- Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies - Xconomy - April 6th, 2020
- Mesoblast's remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress - Small Caps - April 6th, 2020
- Symtomax: the science behind producing high quality medical cannabis - Health Europa - April 6th, 2020
- Stem Cell Therapy for Colon Cancer - The Ritz Herald - April 6th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Publicist360 - April 6th, 2020
- Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - PR Web - April 6th, 2020
- BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics - PRNewswire - April 6th, 2020
- Stem Cell Assay Industry - Market Demand | Recent Trends and Developments Analys - News by aeresearch - April 6th, 2020
- GoBroad Healthcare Group Commences Construction of its Research Hospital in Beijing - PRNewswire - March 30th, 2020
- Reviewing CRYO-CELL International (OTCMKTS:CCEL) and Harsco (OTCMKTS:HSC) - Redmond Register - March 29th, 2020
- Study offers potential breakthrough in the war on antibiotic-resistant superbugs - Yahoo Finance - March 26th, 2020
- European Medicines Agency Grants Orphan Drug Designation to AlloVirs Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy -... - March 26th, 2020
- Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Benzinga - March 26th, 2020
- Over 65s and vulnerable islanders in Jersey to be put in lockdown - ITV News - March 26th, 2020
- Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer - OrthoSpineNews - March 26th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market : Worldwide Business Analysis and Prediction 2020-2025 || Top Players AVRA Medical... - March 26th, 2020
- The Global Cell Culture Market is expected to grow from USD 14,923.23 Million in 2018 to USD 35,236.23 Million by the end of 2025 at a Compound Annual... - March 25th, 2020
- The Global Cell Isolation/Cell Separation Market is expected to grow from USD 5,721.23 Million in 2018 to USD 15,089.25 Million by the end of 2025 at... - March 25th, 2020
- How Crucial is the Cellular Communications Between the Detached Cancerous Cells and Fibroblast for Growing Metastasis - Spark Health MD - March 25th, 2020
- Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine in Patients with COVID-19 Associated Respiratory Illness - P&T... - March 25th, 2020
- Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position - Seeking Alpha - March 25th, 2020
- AlloVir expands its research collaboration with Baylor College of Medicine | - University Business - March 24th, 2020
- Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights - Yahoo Finance - March 22nd, 2020
- How Skin Cells Prepare To Heal Wounds - Technology Networks - March 22nd, 2020
- Physicians Education Resource to Host Live CME Webcast on COVID-19 and Cancer Care - Yahoo Finance - March 22nd, 2020
- A timely Q&A with Bears tight end and 'resident scientist' Ben Braunecker - The Athletic - March 22nd, 2020
- Immunotherapy using 'young cells' offers promising option against cancer - Washington University School of Medicine in St. Louis - March 21st, 2020
- Stem Cell And Regenerative Therapy Market Research Insights Global Industry Outlook Shared in Detailed Report, Forecast size 2024 - Daily Science - March 21st, 2020
- The personal and economic burden of traumatic brain injury - Eagle & Times - March 21st, 2020